Sentences with phrase «endocrine therapy»

No associations were found for women with hormone - receptor - positive tumors and for women who received endocrine therapy.

Thirty - four patients received chemotherapy, and six patients received endocrine therapy.

Phase III Randomized, Placebo - Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy + / - One Year of Everolimus in Patients with High - Risk, Hormone Receptor - Positive and HER2 / neu Negative Breast Cancer.

In Europe, breast cancer patients are commonly treated with endocrine therapy alone,» said Dr. Joanne Mortimer, vice chairwoman of medical oncology at City of Hope Cancer Center in Duarte, Calif..

However, other research has suggested that the estrogen - like effects of isoflavones may reduce the effectiveness of endocrine therapies used to treat breast cancer.

Therefore, common treatments such as endocrine therapy and molecular targeting of the HER - 2 receptor are not effective for this breast cancer subtype.

This decrease was seen only in women with hormone - receptor - negative tumors, and in women who were not treated with endocrine therapy such as tamoxifen.

«Patients with HR +, HER2 - metastatic breast cancer whose disease have progressed after endocrine therapy have significant unmet needs, and we're pleased with the results of this study that demonstrate the potential for palbociclib as an important treatment option for this patient population.»

The study, entitled COMET (Comparison of Operative to Medical Endocrine Therapy) for low - risk ductal carcinoma in situ, received funding through a $ 13.4 million, five - year award from the Patient - Centered Outcomes Research Institute (PCORI), an independent, nonprofit organization authorized by Congress in 2010 to support research that enlightens health care decisions.

«I don't envision a situation where single - agent endocrine therapy would be appropriate any longer for ER + / Her2 - metastatic breast cancer patients.»

The researchers, including scientists from The Genome Institute at Washington University School of Medicine, presented the research titled, «Patient - derived xenograft study reveals endocrine therapy resistance of ER + breast cancer caused by distinct ESR1 gene aberrations.»

Contrast - enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium.

Comprehensive Study Includes All Danish Women Diagnosed with Breast Cancer from 2000 to 2003 who were Indicated for Prosigna and Treated with Endocrine Therapy Accompanying Editorial Highlights Encouraging Data on Clinical Utility in Node - Positive Breast Cancer SEATTLE, Feb..

February 2, 2017 Under and misuse of hormone therapy decreasing, but still high A nationwide cancer registry of almost one million patients treated for hormone - sensitive breast cancer shows that one out of six women who should have received post-surgical treatment known as adjuvant endocrine therapy did not get this recommended component of care, which can reduce the odds of recurrence.

Standard treatments for ER + breast cancer are endocrine therapies such as tamoxifen and aromatase inhibitors.

e3 Breast Cancer Study - evaluating everolimus with endocrine therapy.

«We have identified a subgroup of older patients at sufficiently low risk of recurrence for whom omission of postoperative radiotherapy after breast - conserving surgery and adjuvant endocrine therapy is a reasonable option.

Women who did not receive endocrine therapy as a treatment for their breast cancer had a weaker, but still significant association.

The study, titled «PTK6 regulates growth and survival of endocrine therapy - resistant ER + breast cancer cells,» was published in an online study in NPJ Breast Cancer.

«However, based on our results, we do not see a detrimental effect of soy intake among women who were treated with endocrine therapy, which has been hypothesized to be a concern.

«Endocrine therapies are still the most effective medical therapy for this subtype of breast cancer, and the end goal is to inhibit growth and / or kill ER + breast cancer cells,» said Dr. Irie.

«However, some breast cancer patients still develop metastatic ER + disease despite these common endocrine therapies, so newer treatments are very important and necessary to kill endocrine therapy - resistant cancers.»

In spite of endocrine therapy to suppress hormone receptor activity or hormone exposure, many patients of hormone - dependent cancers encounter de novo or acquired resistance and require more aggressive treatments.

PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR +) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer

PELOPS: Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Study: A Randomized Phase II Study of Palbociclib with Endocrine Therapy versus Endocrine Therapy Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

Since there was no way to predict which women would benefit from such endocrine surgery, Dr. Huggins convinced his colleague Elwood Jensen, PhD, the Charles Huggins Distinguished Professor Emeritus in the University's Ben May Laboratory, to develop a method to identify the estrogen - receptor content of breast cancers and to use that as a predictor of a response to endocrine therapy.

Additionally for patients with ER + or PR + breast cancer who are refractory to endocrine therapy, or patients who have triple negative breast cancer, targeted therapeutic options remain quite limited.

Overholser and colleagues discuss the role of endocrine therapy to reduce risk for breast cancer, and cite interesting data from patients who developed premature ovarian failure due to ovarian irradiation or alkylating chemotherapeutic agents, which demonstrates that these patients were at decreased risk for developing subsequent breast cancer.

Also called anti-estrogen therapy and endocrine therapy, hormonal therapy has been used for over 30 years.